Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around
the world. This type of tuberculosis is very difficult to treat, and many patients die from
it. Drugs of the fluoroquinolone class are very important for treating MDR-TB, but the best
dose of one of the most effective fluoroquinolones, levofloxacin, is not known. This
application proposes a study to determine the best dose of levofloxacin to use in treating
MDR-TB. 120 patients will receive their usual treatment, plus levofloxacin at one of four
doses. The study will be performed in Peru and in South Africa, where MDR-TB is common.
Phase:
Phase 2
Details
Lead Sponsor:
Boston University
Collaborators:
Centers for Disease Control and Prevention Macleods Pharmaceuticals, Ltd National Institute of Allergy and Infectious Diseases (NIAID)